Cost-utility of oral methylprednisolone in the treatment of multiple sclerosis relapses: Results from the COPOUSEP trial
CONCLUSIONS: Oral MP is cost-effective in the treatment of multiple sclerosis relapses and associated with major savings.PMID:34598781 | DOI:10.1016/j.neurol.2021.06.009
Source: Revue Neurologique - Category: Neurology Authors: M Michel E Le Page D A Laplaud R Wardi C Lebrun F Zagnoli S Wiertlewski M Coustans G Edan K Chevreul D Veillard West Network for Excellence in Neuroscience COPOUSEP investigators Source Type: research
More News: Brain | Databases & Libraries | France Health | Health Insurance | Insurance | Methylprednisolone | Multiple Sclerosis | Neurology | Study